



Global Medical REIT Inc. (GMRE)

Updated May 8th, 2023 by Nikolaos Sismanis

Key Metrics

Current Price:	\$8.89	5 Year CAGR Estimate:	11.4%	Market Cap:	\$620.1 M
Fair Value Price:	\$9.45	5 Year Growth Estimate:	3.0%	Ex-Dividend Date:	06/23/2023 ¹
% Fair Value:	94%	5 Year Valuation Multiple Estimate:	1.2%	Dividend Payment Date:	07/07/2023
Dividend Yield:	9.4%	5 Year Price Target	\$10.96	Years Of Dividend Growth:	2
Dividend Risk Score:	F	Retirement Suitability Score:	C	Rating:	Buy

Overview & Current Events

Global Medical REIT Inc. is a net-lease medical office REIT that acquires specialized healthcare facilities, which it leases to national healthcare systems and industry-leading physician groups. The company's portfolio consists of gross investments in real estate worth around \$1.5 billion. They comprise 188 facilities with an aggregate of 4.9 million leasable square feet (LSF) and an aggregate of \$114.9 million worth of annualized base rent. Around 68% of the company's LSF contains Medical Office Buildings (MOB), 18% Inpatient Rehab Facilities (IRF), 6% surgical facilities, and the rest 8% specialized facilities. The \$620.1 million company is based in Bethesda, Maryland.

On May 3rd, 2023, Global Medical reported its Q1 results for the period ending March 31st, 2023. Rental revenues came in at \$36.2 million, an increase of 13.7% year-over-year. The growth reflects an expanded portfolio, including 14 acquisitions closed during fiscal 2022 and one acquisition closed in Q1, as well as rent escalations.

AFFO fell by 4.8% to \$16.0 million due to total expenses rising 25.4%, which was, in turn, mainly due to higher interest expenses. On a per-share basis, AFFO came in a cent lower, at \$0.23, further pressured by a higher share count due to shares issued to fund the company's acquisitions over the past year.

At the end of the quarter, occupancy stood at 97%, 50 bps higher sequentially. Further, the weighted average lease term for the REIT's portfolio was 6.0 years, while the weighted average annual rental escalations were 2.1%. For fiscal 2023, we now expect AFFO/share of \$0.90.

Growth on a Per-Share Basis

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2028
AFFO/shr²	---	---	(\$0.88)	(\$0.03)	\$0.54	\$0.76	\$0.75	\$0.88	\$0.95	\$0.98	\$0.90	\$1.04
DPS	---	---	\$1.02	\$0.74	\$0.80	\$0.80	\$0.80	\$0.80	\$0.82	\$0.84	\$0.84	\$0.88
Shares³	---	---	0.3	9.3	19.6	22.0	33.9	46.3	60.6	65.5	65.5	150.0

Global Medical has rapidly grown its healthcare property portfolio, enjoying robust cash flows and high-quality tenants. The company's solid occupancy and extended average lease period are able to sustain stable financials even under adverse conditions such as those caused by COVID-19 in 2020, a year of record AFFOs at the time. We expect the main catalyst for future AFFO/share growth to be Global Medical's continuous acquisitions and annual rent escalations. We retain our AFFO/share annual growth estimate at 3% through 2028 as a rising-rates environment could hurt the company's bottom-line growth prospects. Higher rates also explain our lower AFFO/share estimate for FY2023.

In terms of its dividend, combined with its preferred shares, the company had been paying out more to shareholders than it was earning up until 2019. This was most likely to attract investors amid the continuous share issuances that it constantly executes to grow its portfolio. It was essential to keep the share price as high as possible during such times. Eventually, Global Medical's AFFO/share caught up with the dividend, as it seems to have been the case over the past couple of years. The second consecutive 2.4% DPS increase in March of 2022 certainly confirms that. That being said, we

¹ Estimated dates based on past dividend dates.

² Being a REIT, AFFO/share is more meaningful metric than EPS. The trust reports high depreciation and amortization levels.

³ Share count is in millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Global Medical REIT Inc. (GMRE)

Updated May 8th, 2023 by Nikolaos Sismanis

expect annualized DPS growth of around 1% in the medium term, as management should now allow for the payout ratio to grow more comfortable over time.

Valuation Analysis

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	Now	2028
Avg. P/AFFO	---	---	---	---	17.0	12.5	15.3	14.2	15.7	12.9	9.9	10.5
Avg. Yld.	---	---	---	7.4%	8.7%	8.4%	7.0%	6.4%	5.4%	6.6%	9.4%	8.1 %

Global Medical's stock currently trades around 9.9 times our expected FY2023 AFFO/share. While the company is growing swiftly, its high dividend as a financing attraction certainly slowed down the per-share growth in both its future AFFO/share and DPS. The humble per-share growth prospects combined with rising rates could justify a discount. Nevertheless, we believe investors undervalue the stock at its current levels and expect the valuation multiple to be expanded toward 10.5. The significant 9.4% yield should also attract investor interest in the stock.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2028
Payout	---	---	---	---	148%	105%	107%	91%	86%	86%	93%	85%

While Global Medical has utilized a slightly risky strategy to grow its portfolio, resulting in displaying unsustainable payout ratios, the portfolio's expansion has caused AFFOs to catch up to DPS. Considering the recent dividend increase and the company's resilient performance during the pandemic, we believe that REIT's dividend should be considered safe. Under a potential recession, we can see the company being in a safer place than the rest of its real estate peers due to its creditworthy tenants and long average leases. No state accounts for more than 18% of its rental revenues, while no tenant accounts for more than 6.4% of its annualized base rent. Hence, the company enjoys adequate diversification qualities. Still, due to its small market cap and immature profile compared to its largest peers, the company faces higher financing costs. Whether it is its hefty dividend (cost of share issuance) or its (admittedly better) cost of debt, which currently stands at 4.3%, the company is likely to be subject to lower profit margins until the macroeconomic landscape improves. Further, we don't see any meaningful competitive advantages, while the REIT's short history as a publicly-traded company is also something to be wary of.

Final Thoughts & Recommendation

Global Medical REIT is a niche healthcare real estate trust featuring robust rental revenues, satisfactory diversification, and an above-average dividend yield, which should remain covered. We forecast annualized returns of around 11.4% through 2028, primarily powered by the 9.4% yield and humble per-share growth estimates, further boosted by a modest valuation tailwind. Shares earn a buy rating.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Global Medical REIT Inc. (GMRE)

Updated May 8th, 2023 by Nikolaos Sismanis

Income Statement Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Revenue		1	2	8	30	53	71	94	116	137
Gross Profit			2	8	28	49	65	83	100	112
Gross Margin		0.0%	96.1%	99.1%	93.9%	93.0%	91.6%	88.4%	86.2%	81.8%
SG&A Exp.		0	1	6	9	10	13	16	16	17
D&A Exp.		0	1	2	10	18	26	37	47	58
Operating Profit		0	1	0	10	22	27	31	37	39
Operating Margin		15.6%	26.0%	1.3%	32.5%	41.8%	38.6%	32.6%	31.9%	28.5%
Net Profit		(0)	(2)	(6)	(0)	13	9	(2)	17.6	19
Net Margin		-68.7%	-78.0%	-77.4%	-0.1%	25.4%	13.1%	-2.1%	15.2%	13.9%
Free Cash Flow		0	(32)	(153)	(240)	(159)	(220)	(184)	(133)	(80)

Balance Sheet Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Total Assets		24	65	227	472	636	885	1,101	1,263	1,393
Cash & Equivalents		0	9	20	5	4	3	6	7	4
Accounts Receivable		0	-	0	1	3	5	6	6	8
Goodwill & Int. Ass.			-	7	29	36	59	80	94	97
Total Liabilities		23	65	72	213	336	425	643	626	744
Accounts Payable			1	1	2	4	5	7	10	14
Long-Term Debt		22	64	67	201	315	386	587	571	694
Shareholder's Equity		2	(0)	155	171	194	355	370	548	558
LTD/E Ratio		12.72	(461)	0.43	0.81	1.17	0.90	1.32	0.92	1.10

Profitability & Per Share Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Return on Assets		-1.8%	-3.6%	-4.3%	0.0%	2.4%	1.2%	-0.2%	1.5%	1.4%
Return on Equity		-20.8%	-203%	-8.2%	0.0%	7.4%	3.4%	-0.5%	3.8%	3.5%
ROIC		-1.8%	-3.7%	-4.5%	0.0%	2.5%	1.3%	-0.2%	1.6%	1.5%
Shares Out.			0.3	9.3	19.6	22.0	33.9	46.3	60.6	65.5
Revenue/Share		2.39	8.25	0.88	1.55	2.42	2.09	2.03	1.91	2.10
FCF/Share		0.52	(127)	(16.4)	(12.2)	(7.22)	(6.51)	(3.98)	(2.19)	(1.22)

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.